Literature DB >> 10385694

Cross-resistance to ionizing radiation in a murine leukemic cell line resistant to cis-dichlorodiammineplatinum(II): role of Ku autoantigen.

P Frit1, Y Canitrot, C Muller, N Foray, P Calsou, E Marangoni, J Bourhis, B Salles.   

Abstract

cis-Dichlorodiammineplatinum(II) (CDDP; cisplatin) is commonly used in combination with ionizing radiation (IR) in the treatment of various malignancies. In vitro, many observations suggest that acquisition of CDDP resistance in cell lines confers cross-resistance to IR, but the molecular mechanisms involved have not been well documented yet. We report here the selection and characterization of a murine CDDP-resistant L1210 cell line (L1210/3R) that exhibits cross-resistance to IR because of an increased capacity to repair double-strand breaks compared with parental cells (L1210/P). In resistant cells, electrophoretic mobility shift assays revealed an increased DNA-end binding activity that could be ascribed, by supershifting the retardation complexes with antibodies, to the autoantigen Ku. The heterodimeric Ku protein, composed of 86-kDa (Ku80) and 70-kDa (Ku70) subunits, is the DNA-targeting component of DNA-dependent protein kinase (DNA-PK), which plays a critical role in mammalian DNA double-strand breaks repair. The increased Ku-binding activity in resistant cells was associated with an overexpression affecting specifically the Ku80 subunit. These data strongly suggest that the increase in Ku activity is responsible for the phenotype of cross-resistance to IR. In addition, these observations, along with previous results from DNA-PK- mutant cells, provide evidence in favor of a role of Ku/DNA-PK in resistance to CDDP. These results suggest that Ku activity may be an important molecular target in cancer therapy at the crossroad between cellular responses to CDDP and IR.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10385694     DOI: 10.1124/mol.56.1.141

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  8 in total

1.  Inhibition of SETMAR-H3K36me2-NHEJ repair axis in residual disease cells prevents glioblastoma recurrence.

Authors:  Ekjot Kaur; Jyothi Nair; Atanu Ghorai; Saket V Mishra; Anagha Achareker; Madhura Ketkar; Debashmita Sarkar; Sameer Salunkhe; Jacinth Rajendra; Nilesh Gardi; Sanket Desai; Prajish Iyer; Rahul Thorat; Amit Dutt; Aliasgar Moiyadi; Shilpee Dutt
Journal:  Neuro Oncol       Date:  2020-12-18       Impact factor: 12.300

2.  Role of insulin-like growth factor-1 signaling pathway in cisplatin-resistant lung cancer cells.

Authors:  Yunguang Sun; Siyuan Zheng; Artour Torossian; Christina K Speirs; Stephen Schleicher; Nicholas J Giacalone; David P Carbone; Zhongming Zhao; Bo Lu
Journal:  Int J Radiat Oncol Biol Phys       Date:  2011-12-22       Impact factor: 7.038

3.  Chrysin impairs genomic stability by suppressing DNA double-strand break repair in breast cancer cells.

Authors:  Anke Geng; Shiya Xu; Yunxia Yao; Zhen Qian; Xiyue Wang; Jiahui Sun; Jingyuan Zhang; Fangfang Shi; Zhixi Chen; Weina Zhang; Zhiyong Mao; Wen Lu; Ying Jiang
Journal:  Cell Cycle       Date:  2022-01-05       Impact factor: 4.534

4.  Equivalence of cell survival data for radiation dose and thermal dose in ablative treatments: analysis applied to essential tremor thalamotomy by focused ultrasound and gamma knife.

Authors:  D Schlesinger; M Lee; G Ter Haar; B Sela; M Eames; J Snell; N Kassell; J Sheehan; J M Larner; J-F Aubry
Journal:  Int J Hyperthermia       Date:  2017-01-31       Impact factor: 3.914

5.  Expression of Ku70 correlates with survival in carcinoma of the cervix.

Authors:  C R Wilson; S E Davidson; G P Margison; S P Jackson; J H Hendry; C M West
Journal:  Br J Cancer       Date:  2000-12       Impact factor: 7.640

Review 6.  The Role of the Core Non-Homologous End Joining Factors in Carcinogenesis and Cancer.

Authors:  Brock J Sishc; Anthony J Davis
Journal:  Cancers (Basel)       Date:  2017-07-06       Impact factor: 6.639

7.  RAD52 variants predict platinum resistance and prognosis of cervical cancer.

Authors:  Ting-Yan Shi; Gong Yang; Xiao-Yu Tu; Jing-Min Yang; Ji Qian; Xiao-Hua Wu; Xiao-Yan Zhou; Xi Cheng; Qingyi Wei
Journal:  PLoS One       Date:  2012-11-29       Impact factor: 3.240

8.  Ku80 is highly expressed in lung adenocarcinoma and promotes cisplatin resistance.

Authors:  Qingshan Ma; Ping Li; Minyu Xu; Jinzhi Yin; Zhenzhong Su; Wei Li; Jie Zhang
Journal:  J Exp Clin Cancer Res       Date:  2012-11-27
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.